<DOC>
	<DOCNO>NCT00096135</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Giving combination chemotherapy together radiation therapy may kill cancer cell . PURPOSE : This clinical trial study well give chemotherapy together radiation therapy work treat patient acute lymphoblastic leukemia relapse CNS and/or testis .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed CNS Testes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy intensified systemic chemotherapy reduced-dose CNS radiotherapy patient acute lymphoblastic leukemia late isolate CNS relapse . - Determine efficacy intensive systemic chemotherapy without testicular radiotherapy patient acute lymphoblastic leukemia late isolate testicular relapse . - Determine toxicity regimens patient . Secondary - Determine whether bone marrow involvement present time extramedullary relapse patient treat regimen . - Correlate pretreatment minimal residual disease outcomes patient treat regimen . - Correlate role host gene polymorphisms toxicity regimens incidence outcome patient . - Determine neuropsychological sequela associate isolated CNS relapse treatment regimens patient . OUTLINE : This pilot , multicenter study . All patient receive common induction , consolidation , re-induction , intensification chemotherapy . Patients stratify maintenance therapy accord site extramedullary relapse ( CNS v testicular ) . - Induction therapy ( week 1-4 ) : Patients receive vincristine IV day 1 , 8 , 15 , 22 ; oral dexamethasone twice daily day 1-28 ; daunorubicin* IV 15 minute day 1 , 8 , 15 ; intrathecal triple therapy** ( ITT ) comprise methotrexate , hydrocortisone , cytarabine day 1 , 8 , 15 , 22 . NOTE : *The total dose anthracyclines study cap 450 mg/m2 . Once dose reach , subsequent dos daunorubicin omit . NOTE : **Patients isolate testicular relapse receive ITT day 1 . In addition , patient isolate testicular relapse also receive high-dose methotrexate IV continuously 24 hour day -14 . Patients clinical sign disease end induction undergo testicular biopsy . Patients CNS disease achieve CNS remission induction therapy receive additional ITT day 29 36 . - Consolidation therapy ( week 5-10 ) : Patients receive high-dose cytarabine IV 3 hour twice daily day 1-2 22-23 pegaspargase intramuscularly ( IM ) day 2 23 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 3 24 continue blood count recover . Patients isolate testicular relapse positive biopsy result end induction undergo testicular radiotherapy daily total 12 fraction consolidation therapy . - Intensification I ( week 11-22 ) : Patients receive high-dose methotrexate leucovorin calcium rescue IV 24 hour day 1 , 22 , 43 , 64 oral mercaptopurine daily day 2-6 , 23-27 , 44-48 , 65-69 . Patients also receive etoposide IV 1 hour cyclophosphamide IV 15-30 minute day 8 , 29 , 50 , 71 . Patients receive ITT* day 15 , 36 , 57 , 78 . NOTE : *Patients isolate testicular relapse receive ITT day 36 78 . - Reinduction therapy ( week 23-26 ) : Patients receive vincristine IV day 1 , 8 , 15 , 22 ; oral dexamethasone twice daily day 1-7 15-21 , daunorubicin IV 15 minute day 1 , 8 , 15 . - Intensification II ( week 27-50 ) : Patients receive high-dose cytarabine IV 3 hour twice daily day 1-2 , 43-44 , 85-86 , 127-128 ; pegaspargase IM day 2 , 44 , 86 , 128 ; ITT* day 22 , 64 , 106 , 148 ; high-dose methotrexate IV continuously 24 hour day 29 , 71 , 113 , 155 ; oral mercaptopurine day 30-34 , 72-76 , 114-118 , 156-160 ; etoposide IV 1 hour cyclophosphamide IV 15-30 minute day 36 , 78 , 120 , 162 . Patients also receive G-CSF SC begin day 3 , 45 , 87 , 129 continue blood count recover . NOTE : *Patients isolate testicular relapse receive ITT day 22 106 . - Chemotherapy radiotherapy ( week 51-54 ) : Patients receive oral dexamethasone twice daily day 1-7 15-21 , vincristine IV day 1 , 8 , 15 , pegaspargase IM day 1 15 . Patients isolated CNS relapse also undergo cranial radiotherapy daily , 5 day week , total 12 fraction . - Maintenance therapy isolate CNS relapse : ( week 55-104 ) : Patients receive dexamethasone PO orIV twice daily day 1-5 ; oral mercaptopurine daily day 1-42 ; methotrexate IM day 1 , 8 , 15 , 22 , 29 , 36 ; vincristine IV cyclophosphamide IV 1 hour day 43 , 50 , 57 , 64 . Treatment repeat every 10 week 5 course . - Maintenance therapy isolate testicular relapse : - ( Weeks 55-74 ) : Patients receive ITT day 1 dexamethasone , mercaptopurine , methotrexate , vincristine , cyclophosphamide maintenance therapy isolate CNS relapse . Treatment repeat every 10 week 2 course . - ( Weeks 75-106 ) : Patients receive vincristine IV day 1 ; dexamethasone orally IV day 1-5 ; oral mercaptopurine day 1-28 ; methotrexate IM day 1 , 8 , 15 , 22 . Treatment repeat every 28 day 8 course . Patients also receive ITT day 1 every 12 week 3 dos . Patients combine testicular CNS relapse receive high-dose methotrexate IV continuously 24 hour day -14 addition chemotherapy radiotherapy administer induction , consolidation , intensification I , reinduction , intensification II , maintenance phase therapy isolate CNS relapse patient . All patient undergo neuropsychological assessment within 3 month completion induction therapy ( cranial radiotherapy ) 2 year completion treatment . Patients follow survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoblastic leukemia ( ALL ) Bprecursor lineage ( Tprecursor lineage close accrual 05/20/10 ) In first bone marrow remission ( M1 morphology ) AND duration first complete remission ≥ 18 month time initial diagnosis First isolate CNS and/or testicular relapse Isolated CNS relapse , define 1 following : WBC ≥ 5/mm^3 cerebrospinal fluid ( CSF ) blast present cytospin Any number WBC CSF immunophenotypic proof leukemic relapse , define follow : Identifiable blast AND 1 following : Blineage ( TdT OR CD10positive 2 consecutive CSF sample obtain 4 week apart ) Tlineage ( TdT AND CD7 OR TdT positivity alone 2 consecutive CSF sample obtain 4 week apart ) ( Closed accrual 05/20/10 ) Isolated testicular relapse , define biopsy proven testicular involvement No Down syndrome No Tcell ALL Tcell nonHodgkin lymphoma No know optic nerve and/or retinal involvement PATIENT CHARACTERISTICS : Age 18 month 29 year relapse Performance status Karnofsky 30100 % ( patient &gt; 16 year age ) OR Lansky 30100 % ( patient ≤ 16 year age ) Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Creatinine adjust accord age follow : No great 0.4 mg/dL ( ≤ 5 month ) No great 0.5 mg/dL ( 6 month 11 month ) No great 0.6 mg/dL ( 1 year23 month ) No great 0.8 mg/dL ( 2 years5 year ) No great 1.0 mg/dL ( 6 years9 year ) No great 1.2 mg/dL ( 10 years12 year ) No great 1.4 mg/dL ( 13 year [ female ] ) No great 1.5 mg/dL ( 13 year 15 year [ male ] ) No great 1.7 mg/dL ( 16 year [ male ] ) OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Cardiovascular Shortening fraction ≥ 27 % echocardiogram OR Ejection fraction ≥ 50 % MUGA Other Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy No prior bone marrow transplantation Chemotherapy Prior total anthracycline dosage ≤ 360 mg/m^2 Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior systemic therapy concurrent extramedullary relapse</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>TdT positive childhood acute lymphoblastic leukemia</keyword>
</DOC>